4.8 Article

Inhibiting Interactions of Lysine Demethylase LSD1 with Snail/Slug Blocks Cancer Cell Invasion

期刊

CANCER RESEARCH
卷 73, 期 1, 页码 235-245

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-12-1739

关键词

-

类别

资金

  1. Fondazione Cassa di Risparmio di Modena
  2. Fondazione Guido Berlucchi
  3. Amici di Lino
  4. NCI [CA095111]
  5. Associazione Italiana Ricerca sul Cancro (AIRC)
  6. Fondazione Angela Serra
  7. Fondazione Cassa di Risparmio di Vignola

向作者/读者索取更多资源

The process of epithelial-mesenchymal transition (EMT) which is required for cancer cell invasion is regulated by a family of E-box-binding transcription repressors, which include Snail (SNAIL1) and Slug (SNAI2). Snail appears to repress the expression of the EMT marker E-cadherin by epigenetic mechanisms dependent on the interaction of its N-terminal SNAG domain with chromatin-modifying proteins including lysine-specific demethylase 1 (LSD1/KDM1A). We assessed whether blocking Snail/Slug-LSD1 interaction by treatment with Parnate, an enzymatic inhibitor of LSD1, or TAT-SNAG, a cell-permeable peptide corresponding to the SNAG domain of Slug, suppresses the motility and invasiveness of cancer cells of different origin and genetic background. We show here that either treatment blocked Slug-dependent repression of the E-cadherin promoter and inhibited the motility and invasion of tumor cell lines without any effect on their proliferation. These effects correlated with induction of epithelial and repression of mesenchymal markers and were phenocopied by LSD1 or Slug downregulation. Parnate treatment also inhibited bone marrow homing/engraftment of Slug-expressing K562 cells. Together, these studies support the concept that targeting Snail/Slug-dependent transcription repression complexes may lead to the development of novel drugs selectively inhibiting the invasive potential of cancer cells. Cancer Res; 73(1); 235-45. (C) 2012 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation

Milena Perrone, Claudia Chiodoni, Mara Lecchi, Laura Botti, Barbara Bassani, Annamaria Piva, Elena Jachetti, Matteo Milani, Daniele Lecis, Elda Tagliabue, Paolo Verderio, Sabina Sangaletti, Mario P. Colombo

Summary: Cancer can reprogram the bone marrow niche through the BM mesenchymal stem cells (MSC) and IL-1B/ATF3 signaling pathway, which promotes myeloid cell differentiation and tumor development. The expression of CD11b thorn population in the peripheral blood can be used as a potential biomarker for early diagnosis of breast cancer. This study suggests that targeting IL-1B or ATF3 may have therapeutic benefits for breast cancer patients.

CANCER RESEARCH (2023)

Article Oncology

Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement

Riccardo Ray Colciago, Irene Fischetti, Carlotta Giandini, Eliana La Rocca, Tiziana T. Rancati, Alicia Rejas Mateo, Mario Paolo Colombo, Laura Lozza, Claudia Chiodoni, Elena Jachetti, Maria Carmen De Santis

Summary: Oncological treatments are rapidly changing with the introduction of targeted anticancer drugs and regimens, and radioimmunotherapy is emerging as a promising field. This review provides an overview of the synergistic use of radiotherapy and immunotherapy and addresses important questions about its implementation, the patient selection criteria, and when it becomes standard clinical practice.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Article Oncology

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids

Eleonora Cesari, Alessandra Ciucci, Marco Pieraccioli, Cinzia Caggiano, Camilla Nero, Davide Bonvissuto, Francesca Sillano, Marianna Buttarelli, Alessia Piermattei, Matteo Loverro, Floriana Camarda, Viviana Greco, Maria De Bonis, Angelo Minucci, Daniela Gallo, Andrea Urbani, Giuseppe Vizzielli, Giovanni Scambia, Claudio Sette

Summary: High grade serous ovarian cancer (HGSOC) is a highly lethal form of cancer, and there is a need for targeted therapies and overcoming chemotherapy resistance. CDK12 and CDK13 have been identified as potential therapeutic targets in HGSOC, but their effects and potential synergy with other drugs are not well understood.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Oncology

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model

Elisa Bianchi, Sebastiano Rontauroli, Lara Tavernari, Margherita Mirabile, Francesca Pedrazzi, Elena Genovese, Stefano Sartini, Massimiliano Dall'Ora, Giulia Grisendi, Luca Fabbiani, Monica Maccaferri, Chiara Carretta, Sandra Parenti, Sebastian Fantini, Niccolo Bartalucci, Laura Calabresi, Manjola Balliu, Paola Guglielmelli, Leonardo Potenza, Enrico Tagliafico, Lorena Losi, Massimo Dominici, Mario Luppi, Alessandro Maria Vannucchi, Rossella Manfredini

Summary: BM fibrosis is a major pathology in myelofibrosis and is associated with overexpression of OPN protein. ERK1/2 is a key regulator of OPN production, and inhibiting ERK1/2 activity can reduce OPN production and hinder the development of BM fibrosis. Targeting OPN and ERK1/2 could be potential therapeutic strategies for myelofibrosis.

LEUKEMIA (2023)

Article Oncology

JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer

Bianca Cioni, Silvia Ratti, Annamaria Piva, Irene Tripodi, Matteo Milani, Francesca Menichetti, Tiziana Langella, Laura Botti, Loris De Cecco, Claudia Chiodoni, Daniele Lecis, Mario P. Colombo

Summary: Breast cancer, especially the luminal subtype, is a common and threatening disease due to therapy resistance. JMJD6, known for its epigenetic activity, is found to have a negative prognostic value in luminal breast cancer and can regulate cancer cell pathways. This study discovers a novel function of JMJD6, showing that its genetic inhibition in breast cancer cells reduces lipid droplet formation and ANXA1 expression, ultimately preventing tumor aggressiveness by inhibiting M2-type macrophage polarization in the tumor microenvironment.

MOLECULAR CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1

Valentina Panzeri, Marco Pieraccioli, Eleonora Cesari, Pierre de la Grange, Claudio Sette

Summary: Transcription-associated cyclin-dependent kinases (CDKs) regulate the transcription cycle through phosphorylation of RNA polymerase II (RNAPII). This study found that inhibiting CDK12 and CDK13 impaired splicing of specific promoter-proximal introns. The inhibition of CDK12/13 disrupted the interaction between SF3B1 and RNAPII, resulting in retention of these introns and a synergistic effect with another inhibitor on cell survival and cancer progression.

NUCLEIC ACIDS RESEARCH (2023)

Article Cell Biology

Adding pieces to the puzzle of differentiated-to-anaplastic thyroid cancer evolution: the oncogene E2F7

Mila Gugnoni, Eugenia Lorenzini, Italo Faria do Valle, Daniel Remondini, Gastone Castellani, Federica Torricelli, Elisabetta Sauta, Benedetta Donati, Moira Ragazzi, Francesco Ghini, Simonetta Piana, Alessia Ciarrocchi, Gloria Manzotti

Summary: This study validated specific gene signatures in the transition from differentiated thyroid carcinoma (DTC) to anaplastic thyroid cancer (ATC) and identified the E2F7 gene as a key player in this process. Down-regulation of E2F7 reduced the aggressiveness of ATC cells.

CELL DEATH & DISEASE (2023)

Article Cell Biology

An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization

Federica Torricelli, Elisabetta Sauta, Veronica Manicardi, Vincenzo Dario Mandato, Andrea Palicelli, Alessia Ciarrocchi, Gloria Manzotti

Summary: This study identified potential drug candidates for high-risk endometrial cancer using a computational drug repurposing approach.
Article Oncology

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

Caterina Cascini, Chiara Ratti, Laura Botti, Beatrice Parma, Valeria Cancila, Adriana Salvaggio, Cristina Meazza, Claudio Tripodo, Mario P. Colombo, Claudia Chiodoni

Summary: Osteosarcoma (OS) is the most common primary bone tumor in children and adolescent. In this study, it was found that intralesional administration of a TLR9 agonist can effectively inhibit tumor growth and also have therapeutic effects on untreated contralateral lesions. The findings suggest that TLR9 agonist can act as an in situ anti-tumor vaccine, activating innate and adaptive immune responses to suppress tumor growth.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Oncology

Ex vivo mapping of enhancer networks that define the transcriptional program driving melanoma metastasis

Veronica Manicardi, Mila Gugnoni, Elisabetta Sauta, Benedetta Donati, Emanuele Vitale, Federica Torricelli, Gloria Manzotti, Simonetta Piana, Caterina Longo, Francesco Ghini, Alessia Ciarrocchi

Summary: Mortality from vmelanoma is associated with metastatic disease, but the mechanisms leading to spreading of the cancer cells remain obscure. Spatial profiling revealed that melanoma is characterized by a high degree of heterogeneity, which is established by the ability of melanoma cells to switch between different phenotypical stages. This plasticity, likely a heritage from embryonic pathways, accounts for a relevant part of the metastatic potential of these lesions, and requires the rapid and efficient reorganization of the transcriptional landscape of melanoma cells.

MOLECULAR ONCOLOGY (2023)

Article Multidisciplinary Sciences

Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects

S. Cortellino, V. Quagliariello, G. Delfanti, O. Blazevits, C. Chiodoni, N. Maurea, A. Di Mauro, F. Tatangelo, F. Pisati, A. Shmahala, S. Lazzeri, V. Spagnolo, E. Visco, C. Tripodo, G. Casorati, P. Dellabona, V. D. Longo

Summary: This study explores the use of periodic cycles of a fasting-mimicking diet (FMD) to reduce the side effects caused by immunotherapy in cancer treatment. The combination of FMD cycles with immunotherapy shows promising results in delaying cancer growth and reducing cardiotoxicity.

NATURE COMMUNICATIONS (2023)

Review Oncology

Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses

Magda Zanelli, Francesca Sanguedolce, Maurizio Zizzo, Valentina Fragliasso, Giuseppe Broggi, Andrea Palicelli, Giuseppe Gaetano Loscocco, Camilla Cresta, Cecilia Caprera, Matteo Corsi, Giovanni Martino, Alessandra Bisagni, Marialisa Marchetti, Nektarios Koufopoulos, Paola Parente, Rosario Caltabiano, Stefano Ascani

Summary: This paper focuses on the clinical and pathological features of lymphoblastic lymphoma of B- or T-cell origin and mantle cell lymphoma, particularly its blastoid variant, involving the skin. It emphasizes the importance of precise diagnosis for different diseases with similar blastic characteristics that have different outcomes and require distinct therapeutic strategies in patient management. The assessment of skin biopsies of hematological neoplasms with blastic features poses diagnostic challenges and requires consideration of a wide range of differential diagnoses.

CANCERS (2023)

Review Oncology

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?

Claudia Piombino, Marco Oltrecolli, Elena Tonni, Marta Pirola, Rossana Matranga, Cinza Baldessari, Stefania Pipitone, Massimo Dominici, Roberto Sabbatini, Maria Giuseppa Vitale

Summary: De novo metastatic hormone-sensitive prostate cancer usually has a poor prognosis, but recent advancements in new hormonal agents and combination therapy have slightly improved outcomes. Ongoing clinical trials are exploring new therapeutic approaches and personalized treatment options based on genomic features and biomarker-guided treatment.

CANCERS (2023)

Article Oncology

A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer

C. Chiodoni, S. Sangaletti, M. Lecchi, C. M. Ciniselli, V Cancila, I. Tripodi, C. Ratti, G. Talarico, S. Brich, L. De Cecco, P. Baili, M. Truffi, F. Sottotetti, F. Piccotti, C. Tripodo, G. Pruneri, T. Triulzi, F. Corsi, V Cappelletti, S. Di Cosimo, P. Verderio, M. P. Colombo

Summary: This study identified three genes, CSTB, CCDC91, and ITGB1, associated with early locoregional recurrence (LRR) in luminal-like breast cancer patients. These genes could serve as a useful tool for predicting early recurrence risk and guiding treatment decisions.

ESMO OPEN (2023)

暂无数据